历经十年沉淀,CDK4/6抑制剂这一细分市场在规模上已经成长为近130亿美元的黄金赛道。但正所谓城头变幻大王旗,CDK4/6赛道的头牌在2024年也从辉瑞Ibrance(哌柏西利)正式交接到礼来Verzenio(阿贝西利)手中。2015年,Ibrance(哌柏西利)作为全球首个上市的CDK4/6抑制剂横空出世。该药有效克服了HR+/HER2-晚期乳腺癌患者内分泌治疗耐药的问题,延长了患者的生存期,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.